

Disease Modification in Individuals with
MODERATE-TO-SEVERE
RHEUMATOID ARTHRITIS:
Optimizing Treatment Through the Finely Tuned Selectivity for JAKs



MEETING INFO

TeleECHO Presentation

Wednesday, February 9, 2022

3:00 – 4:00 PM ET

2:00 – 3:00 PM CT

1:00 – 2:00 PM MT

12:00 – 1:00 PM PT

FACULTY

Jon T Giles, MD MPH

Associate Professor of Medicine

Division of Rheumatology

Columbia University, College of Physicians & Surgeons

New York, NY



This activity is provided by Med Learning Group.

This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is supported by an educational grant from AbbVie Inc.



Disease Modification in Individuals with **MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS:** Optimizing Treatment Through the Finely Tuned Selectivity for JAKs

Agenda

I. Managing Rheumatoid Arthritis (RA)

- a. Features of rheumatoid arthritis
- b. RA pathophysiology
- c. Treatment options for RA
- d. Guideline recommended care of RA
 - i. Initial DMARD choice
 - ii. Options after inadequate response to initial therapy
- e. Treating to target

II. JAK Inhibitors for the Management of Moderate-to-Severe RA

- a. JAK inhibitor mechanism of action and selectivity
- b. Review of clinical trial data of the efficacy and safety of JAK inhibitors:
 - i. Monotherapy
 - ii. Combination therapy
 - iii. Patients with inadequate response to methotrexate (MTX IR)
 - iv. MTX naive populations
 - v. Long-term safety data

III. Application of Societal Guidelines for Moderate-to-Severe Disease – ACR & EULAR

- a. Focus on JAK inhibition and its place in management of patients
- b. Comorbid conditions and RA treatment considerations

IV. Conclusions

V. Interactive Case Studies

VI. Q & A

Disease Modification in Individuals with Moderate-to-Severe Rheumatoid Arthritis: Optimizing Treatment Through the Finely Tuned Selectivity for JAKs

FACULTY

Jon T. Giles, MD, MPH (Program Chair)

Associate Professor of Medicine

Division of Rheumatology

Columbia University, College of Physicians & Surgeons

New York, NY

PROGRAM OVERVIEW

This TeleECHO series will explore the use of JAK inhibitors for the management of rheumatoid arthritis (RA) through interactive case studies. Faculty will review emerging efficacy and safety data, discuss guideline recommended care of RA, and help clinicians identify candidates for treatment with JAK inhibitors.

TARGET AUDIENCE

This CME initiative is designed to meet the educational needs of rheumatologists, nurses and allied healthcare professionals involved in the care of patients with rheumatoid arthritis.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

- Review the members of the JAK family, involvement in RA pathology, and selectivity of JAK targets and associated effects
- Discuss the clinical trials findings for Janus Kinase inhibitors in patients with moderate-to-severe RA
- Describe the application of ACR/EULAR management recommendations to clinical practice for patients with moderate-to-severe rheumatoid arthritis

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group will designate each virtual live meeting and simulcast for a maximum of 1.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the live-virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with rheumatoid arthritis.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education by the American Nurses Credentialing Center's Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member	Disclosures
Jon T. Giles, MD, MPH	Discloses that he has received consulting fees from AbbVie, Pfizer, Bristol Myers Squibb, UCB, Eli Lilly, and Gilead. He has also provided contracted research to Pfizer.

CME Content Review

The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN

Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.

Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.

Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.

Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.

Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.

Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.

Daniel Dasilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this live virtual activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures.
2. Participate in the web-based live activity.
3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at <http://medlearninggroup.com/privacy-policy/>

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com



This activity is provided by Med Learning Group



This activity is Co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is supported by an educational grant from AbbVie Inc.

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

***Disease Modification in Individuals with
Moderate-to-Severe Rheumatoid Arthritis:
Optimizing Treatment Through the
Finely Tuned Selectivity for JAKs***

Jon T. Giles, MD, MPH

Associate Professor of Medicine
Division of Rheumatology
Columbia University College of Physicians & Surgeons
New York, NY

Accreditation

- Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
- Ultimate Medical Academy / CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission of Accreditation.
- This educational activity is applicable for CME and CNE credit. Please complete the necessary electronic evaluation to receive credit.

Disclosures

- Jon T. Giles, MD, MPH has received consulting fees from AbbVie, Bristol Myers Squibb, Lilly, Gilead, and UCB. He also states a financial relationship with Pfizer.
- During the course of this lecture, Dr. Giles may mention the use of medications for both FDA-approved and non-approved indications.

This activity is supported by an educational grant from AbbVie Inc.

Learning Objectives

- Review the members of the JAK family, their involvement in RA pathology, and selectivity of JAK targets and associated effects
- Discuss the clinical trials findings for JAK inhibitors in patients with moderate-to-severe RA
- Describe the application of ACR/EULAR management recommendations to clinical practice for patients with moderate-to-severe rheumatoid arthritis

JAK = Janus kinase; RA = rheumatoid arthritis; ACR = American College of Rheumatology; EULAR = European League Against Rheumatism.

Features of Rheumatoid Arthritis

- RA is autoimmune disorder

- Prevalence 1% worldwide

- 3–4 million in U.S

- Peak incidence in 4th to 6th decade of life

- Female:male ratio of 3:1


- Characterized by:

- Synovitis

- Systemic inflammation


- Extra-articular features

- Increased morbidity/mortality



RA = rheumatoid arthritis; QoL = quality of life.

RA Pathobiology



ACPA = anti-citrullinated protein antibody; APC = antigen-presenting cell; IFN = interferon; IL = interleukin; MMP = metalloproteinase; RANKL = receptor activator of nuclear factor-κB ligand; TNF = tumor necrosis factor.

Adapted from Smolen JS, Steiner G. *Nat Rev Drug Discov.* 2003;2:473-488. Choy EH, Panayi GS. *N Engl J Med.* 2001;344:907-916. Silverman GJ, Carson DA. *Arthritis Res Ther.* 2003;5(suppl 4):S1-S6.

Disease-Modifying Pharmacotherapies for RA Available in US

Oral non-biologics

Methotrexate
Sulfasalazine
Hydroxychloroquine
Leflunomide
Azathioprine
Cyclosporine
Tacrolimus
Cyclophosphamide

Prednisone

Selective cytokine inhibitors

TNF inhibitors

Etanercept
Infliximab
Adalimumab
Certolizumab
Golimumab

IL-1 inhibitors

Anakinra

IL-6 inhibitors

Tocilizumab
Sarilumab

B-cell depletion

Rituximab

T cell co-stimulation blockade

Abatacept


JAK inhibition

Tofacitinib
Baricitinib
Upadacitinib

US = United States; JAK = Janus kinase.

Köhler BM, et al. *J Clin Med*. 2019;8:938.

Targets of Therapy in RA



Adapted from Smolen JS, Steiner G. *Nat Rev Drug Discov*. 2003;2:473-488. Choy EH, Panayi GS. *N Engl J Med*. 2001;344:907-916. Silverman GJ, Carson DA. *Arthritis Res Ther*. 2003;5(suppl 4):S1-S6.

Initial DMARD Choice

American College of Rheumatology (ACR) 2021 RA Treatment Guideline

Initiation of DMARD treatment of patients with RA	
ACR recommendations	Certainty of evidence
Initiation of treatment in DMARD-naïve patients with MODERATE-TO-HIGH disease activity	
Methotrexate (MTX) monotherapy is strongly recommended over:	Very low/low
Hydroxychloroquine or sulfasalazine	Very low/moderate
bDMARD or tsDMARD monotherapy	Low/very low
Combination of MTX + non-TNFi bDMARD or tsDMARD	
MTX monotherapy is conditionally recommended over:	
Leflunomide	Low
Dual or triple csDMARD therapy	Moderate
Combination of MTX + TNFi	Low
Initiation of csDMARD without short-term (<3 months) glucocorticoids is conditionally recommended over initiation of csDMARD with short-term glucocorticoids	Very low
Initiation of csDMARD without longer-term (≥3 months) glucocorticoids is strongly recommended over initiation of csDMARD with longer-term glucocorticoids	Moderate
Initiation of treatment in DMARD-naïve patients with LOW disease activity	
Hydroxychloroquine is conditionally recommended over other csDMARDs	Very low
Sulfasalazine is conditionally recommended over MTX	Very low
MTX is conditionally recommended over leflunomide	Very low
Initiation of treatment in csDMARD-treated, but MTX-naïve, patients with MODERATE-TO-HIGH disease activity	
MTX monotherapy is conditionally recommended over combination of MTX + bDMARD or tsDMARD	Moderate/very low

DMARD = disease-modifying antirheumatic drug; bDMARD = biologic DMARD; tsDMARD = targeted-synthetic DMARD; csDMARD = conventional synthetic DMARD; TNFi = TNF inhibitor.

Fraenkel L, et al. *Arthritis Care Res.* 2021;73:924-939.

Failure of Initial Treatment Choice

ACR 2021 RA Treatment Guideline

Treatment modification following inadequate response to initial treatment	
Recommendations	Certainty of evidence
T2T approach is strongly recommended over usual care for patients who have not been previously treated with bDMARDs or tsDMARDs	Low
T2T approach is conditionally recommended over usual care for patients who have had an inadequate response to bDMARDs or tsDMARDs	Very low
Minimal initial treatment goal of low disease activity is conditionally recommended over goal of remission	Low
Addition of a bDMARD or tsDMARD is conditionally recommended over triple therapy for patients taking maximally tolerated doses of MTX who are not at target	Very low
Switching to bDMARD or tsDMARD of different class is conditionally recommended over switching to bDMARD or tsDMARD belonging to same class for patients taking bDMARD or tsDMARD who are not at target	Very low
Addition of/switching to DMARDs is conditionally recommended over continuation of glucocorticoids for patients taking glucocorticoids to remain at target	Very low
Addition of/switching to DMARDs (± IA glucocorticoids) is conditionally recommended over use of IA glucocorticoids alone for patients taking DMARDs who are not at target	Very low

T2T = treat-to-target; IA = intraarticular.

Fraenkel L, et al. *Arthritis Care Res.* 2021;73:924-939.

The Principles of Treating to Target

- T2T by measuring disease activity and adjusting therapy accordingly will result in better patient outcomes
- The primary target for treatment should be clinical remission, defined as the absence of signs and symptoms of significant inflammatory disease activity
- In some cases, low disease activity (LDA) may be an acceptable treatment goal, particularly in patients with long-standing, established disease

Smolen JS, et al. *Ann Rheum Dis*. 2010;69:631-637.

So, Can T2T Be Implemented in the Real World? A First Look...

- RA BIODAM (**B**IOmarkers of joint **DAM**age): RA registry in 10 countries^{1,2}
 - At 41% of visits, T2T protocol was not implemented¹
 - Main reason: physician felt current treatment was adequate (69%)²
- CORRONA (**C**onsortium of Rheumatology Researchers of North America)^{3,4}
 - Failure to escalate occurred at ~50% of visits
 - 2 main reasons: doctor said treatment needed more time to work (eg, 3 more months) or patient refused
- Implications for patients with persistently active disease
 - Patients and doctors feel that current treatment is “good enough”
 - Patients are risk averse to add/change therapy


1. Ramiro S, et al. *Ann Rheum Dis*. 2020;79:453-459. 2. Maksymowych WP, et al. *Arthritis Rheumatol*. 2014;66(suppl 10): abstract 2912. 3. Harrold L, et al. *Arthritis Rheumatol*. 2015;67(suppl 10): abstract 3185. 4. Harrold LR, et al. *Arthritis Care Res (Hoboken)*. 2018;70:379-387.

Unmet Need for RA Treatments

- Rates of “low disease activity” and “remission” have improved over time
 - 5 years after symptom onset in 2009, 45% reached sustained remission (SR) compared with only 16% in 1999
 - Largely due to the availability of new treatments and adoption of T2T
- However, SR is only observed in ~25%
 - Fluctuating disease activity/flares
 - Secondary loss of response
 - Treatment resistance in a subset
 - Intolerance/side effects
- Complete treatment refractoriness is rare

Einarsson JT, et al. *Rheumatology (Oxford)*. 2020;59:205-212. Mierau M, et al. *Rheumatology (Oxford)*. 2007;46:975-979. Prince FHM, et al. *Arthritis Res Ther*. 2012;14:R68.



Signaling by Type I/II Cytokine Receptors and JAK Inhibitors



*Not FDA approved.

GH = growth hormone; Epo = erythropoietin; GM-CSF = granulocyte macrophage colony-stimulating factor; TYK = tyrosine kinase; TOFA = tofacitinib; BARI = baricitinib; UPA = upadacitinib; FIL = filgotinib; PEF = peficitinib.


Fragoulis GE, et al. *J Allergy Clin Immunol*. 2021;148:941-952.



TOFA vs
TOFA + MTX vs
ADA + MTX
in MTX-IR

ORAL Strategy: Efficacy

Primary Endpoint: ACR50 at 6 Months



- Tofacitinib + MTX non-inferior to adalimumab + MTX
- Tofacitinib monotherapy did not meet non-inferiority criteria compared with tofacitinib + MTX
- Tofacitinib monotherapy did not meet non-inferiority criteria compared with adalimumab + MTX

Fleischmann R, et al. *Lancet*. 2017;390:457-468.

ORAL Strategy

AEs, Serious AEs, and Discontinuations

	TOFA monotherapy (n = 384)	TOFA + MTX (n = 376)	ADA + MTX (n = 386)
Total number of AEs, n	598	652	620
Patients with AEs, n (%)	226 (59%)	231 (61%)	253 (66%)
Patients with treatment-related AEs, n (%)	101 (26%)	111 (30%)	133 (35%)
Patients with serious AEs, n (%)	35 (9%)	27 (7%)	24 (6%)
Patients discontinuing due to AEs, n (%)	23 (6%)	26 (7%)	37 (10%)
Patients with severe AEs, n (%) (defined by investigator)	24 (6%)	17 (5%)	23 (6%)
Deaths, n (%)	2 (1%)	0	0
AEs of special interest, n (%)			
Serious infections	6 (2%)	10 (3%)	6 (2%)
HZ (serious and non-serious)	4 (1%)	8 (2%)	6 (2%)
HZ (serious and non-serious) in vaccinated patients	1/69 (1%)	2/75 (3%)	0/72 (0%)
Opportunistic infections (not TB)	2 (1%)	1 (< 1%)	2 (1%)
TB	0	2 (1%)	0
MACE (non-fatal)	0	0	2 (1%)
Malignancy (not non-melanoma skin cancer)	1 (< 1%)	0	0
Non-melanoma skin cancer	2 (1%)	0	1 (< 1%)

AE = adverse event; HZ = herpes zoster; TB = tuberculosis; MACE = major adverse cardiovascular event.

Fleischmann R, et al. *Lancet*. 2017;390:457-468.

Venous Thromboembolism (VTE) With JAK Inhibitors

Primary analysis: VTE events identified from inpatient claims with as-treated follow-up approach

Data source and exposure group	VTE events, n	Total PYs of follow-up	Incidence rate per 100 PYs (95% CI)	Unadjusted HR (95% CI)	Propensity score-adjusted HR (95% CI)
Truven MarketScan					
TNFi initiators (n = 32,164)	98	28,951	0.34 (0.27–0.41)	Reference	Reference
TOFA initiators (n = 1910)	8	1326	0.60 (0.26–1.19)	1.70 (0.82–3.49)	1.55 (0.75–3.18)
Medicare claims					
TNFi initiators (n = 16,091)	117	12,660	0.92 (0.76–1.11)	Reference	Reference
TOFA initiators (n = 995)	<11*	625	1.12 (0.45–2.31)	1.16 (0.54–2.49)	1.12 (0.52–2.40)
Pooled					
TNFi initiators (n = 48,255)	215	41,611	0.52 (0.45–0.59)	Reference	Reference
TOFA initiators (n = 2905)	15	1951	0.77 (0.43–1.27)	1.42 (0.84–2.40)	1.33 (0.78–2.24)

- Higher rates of VTE noted in interim analysis of large safety study for tofacitinib 10 mg BID
- EMA recommended caution for use of JAK inhibitors for people at risk for VTE
- Rates of VTE across phase 3 trials of all studied JAK inhibitors $\approx$ 0.5/1000 PYs


*Actual number suppressed; required by data use agreement with Medicare and Medicaid Services for counts <11.

HR = hazard ratio; CI = confidence interval; PY = person-year; EMA = European Medicines Agency.

Desai RJ, et al. *Arthritis Rheumatol.* 2019;71:892-900. Sandborn WJ, et al. *Aliment Pharmacol Ther.* 2019;50:1068-1076. EMA (www.ema.europa.eu/en/medicines/human/referrals/xeljanz). Accessed 12/21/2021.

Efficacy and Safety of Tofacitinib (JAK 1/3) + MTX in TNFi-IR Patients

Phase 3 trial outcomes for treatments at 3 months¹



- Tofacitinib has consistent, manageable safety profile across studies; no new safety signals¹
- Consistent safety through 114 months; sustained clinical efficacy through 96 months²
- 5-year analysis of AEs with tofacitinib vs bDMARDs reported in CORRONA RA registry shows higher incidence of HZ but not MACE or other serious infections³


* $P \leq .05$, † $P < .0001$ vs PBO.

PBO = placebo; SE = standard error; BL = baseline.

1. Burmester GR, et al. *Lancet.* 2013;381:451-460. 2. Wollenhaupt J, et al. *ACR/ARHP* 2017: abstract 522. 3. Kremer J, et al. *EULAR* 2019: abstract OP0028.


Efficacy and Safety of Baricitinib (JAK 1/2) in bDMARD-IR Patients

RA-BEACON phase 3 trial^{1,2}



RA-BEAM phase 3 trial³

Patients meeting/exceeding clinically relevant improvement thresholds at week 12 after rescue



VAS = visual analog scale; FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue; MJS = morning joint stiffness; PCS = physical component score; MCS = mental component score; min = minute(s).

1. Genovese MC, et al. *N Engl J Med*. 2016;374:1243-1252 and supplement. 2. Genovese MC, et al. *Rheumatology (Oxford)*. 2018;57:900-908. 3. Fautrel B, et al. ACR/ARHP 2017: abstract 508.

Baricitinib


- Baricitinib led to more AEs (including infections) than placebo¹
- Most common infections were respiratory tract, urinary tract, bronchitis¹
- Rates of serious AEs through week 24 were similar among patient groups¹
- Post-hoc analysis of RA-BEACON: ORs favored use of baricitinib over placebo regardless of bDMARD history (number or type)²
- 7-year integrated safety analysis from phase 3 trials show increased risk for HZ and deep vein thrombosis/pulmonary embolism but not for malignancy³

OR = odds ratio.

1. Genovese MC, et al. *N Engl J Med*. 2016;374:1243-1252. 2. Genovese MC, et al. *Rheumatology (Oxford)*. 2018;57:900-908. 3. Genovese MC, et al. EULAR 2019: abstract THU0078.

Efficacy and Safety of Upadacitinib (JAK 1) in bDMARD-IR Patients

Phase 3 trial SELECT-BEYOND



1. Genovese MC, et al. *Lancet*. 2018;391:2513-2524. 2. Genovese MC, et al. ACR/ARHP 2017: abstract 10L.

Upadacitinib


- In a post-hoc analysis, upadacitinib showed comparable efficacy whether administered with methotrexate or with other non-methotrexate csDMARDs¹
- UPA treatment also resulted in significant, clinically meaningful improvements in PROs among patients²
- Pooled safety analysis across phase 3 trials showed higher risk for serious infections and HZ but not for VTE, MACE, or malignancy (vs comparators)³
- Safety and efficacy remained consistent after 60 weeks of treatment⁴

PRO = patient-reported outcome.

1. Kremer J, et al. *Ann Rheum Dis*. 2019;78(suppl 2):A749 (abstract FRI0155). 2. Strand V, et al. *Ann Rheum Dis*. 2018;77(suppl 2):990 (abstract SAT0255). 3. Cohen SB, et al. *Ann Rheum Dis*. 2019;78(suppl 2):357 (abstract THU0167). 4. Genovese MC, et al. *Ann Rheum Dis*. 2019;78(suppl 2):360 (abstract THU0172).

Efficacy and Safety of Upadacitinib vs Abatacept in bDMARD-IR Patients

- Phase 3 trial SELECT-CHOICE
- Assessed non-inferiority (primary outcome) and superiority (secondary outcome) of oral upadacitinib 15 mg daily vs IV abatacept monthly for change in DAS28-CRP
 - Stable background non-biologic DMARDs continued
 - Primary endpoint measured at week 12
- Upadacitinib was non-inferior and superior to abatacept at week 12
 - Primary driver was change in CRP
- Remission at week 12 higher for upadacitinib vs abatacept
 - 30.0% vs 13.3% ($P < .001$)
- Adverse events higher for upadacitinib
 - Serious infection, MACE, VTE
 - HZ not higher, but low frequency at week 12




IV = intravenous.

Rubbert-Roth A, et al. *N Engl J Med*. 2020;383:1511-1521.

Longer Term Safety of Upadacitinib from Open-Label Trial Extensions Across Indications and Compared with Adalimumab and MTX

AEs of special interest (events/100 PY [95% CI]) across RA, PsA, and AS




4298 patients received ≥ 1 dose UPA 15 mg (n = 3209 RA; n = 907 PsA; n = 182 AS)

PsA = psoriatic arthritis; AS = ankylosing spondylitis; NMSC = non-melanoma skin cancer; CPK = creatine phosphokinase.

Burmester G, et al. ACR 2021, abstract 1691.

ORAL Surveillance Safety Trial: Tofacitinib vs TNF Inhibitors

Randomized, Open-Label Phase 4 Non-inferiority Trial




- Co-primary outcomes: MACE and malignancy (combined TOFA doses vs TNFi)
 - Non-inferiority margin set at 1.8
- After a signal for VTE was detected for TOFA 10 mg BID in Feb 2019, patients on this dose were changed to 5 mg BID
- The study was completed once ≥ 1500 patients were followed for ≥ 3 years, ≥ 103 MACE were reported, and ≥ 138 malignancies excluding NMSC were reported

CVD = cardiovascular disease; ETN = etanercept; QW = each week; RoW = rest of world.

Ytterberg SR, et al. ACR 2021, abstract 831

ORAL Surveillance Safety Trial: Tofacitinib vs TNF Inhibitors

HRs (95% CI) and IRs (95% CI) for adjudicated MACE and malignancies




- Combined tofacitinib doses were not non-inferior to TNFi for either MACE or malignancy
- No difference between tofacitinib doses
- Most MACE and malignancies occurred in patients > 65 years and/or ever smokers
- MACE difference for tofacitinib vs TNFi primarily for MI
- Malignancy difference for tofacitinib vs TNFi primarily for lung cancer, lymphoma, and NMSC

IR = incidence rate; NNH = number needed to harm; MI = myocardial infarction.

Ytterberg SR, et al. ACR 2021, abstract 831. Charles-Schoeman C, et al. ACR 2021, abstract 958. Curtis J, et al. ACR 2021, abstract 1940.

RA Is an Independent Risk Factor for Cardiovascular Events*





*MI and stroke.

CV = cardiovascular.

Solomon DH, et al. *Ann Rheum Dis*. 2006;65:1608-1612.

DMARDs and CVD Events in RA

- Methotrexate and TNF inhibitors are most studied
- Observational data only
- Comparison group problematic
- MTX use associated with 28% reduction in all CVD events across 8 cohort studies (HR = 0.72 [95% CI, 0.57–0.91], $P = .007$)¹
- TNFi use associated with 30% reduction in CVD events across 16 cohort studies (HR = 0.70 [95% CI, 0.54–0.90], $P = .005$)¹
- Abatacept similar to etanercept from claims data²
- Tocilizumab similar to etanercept in head-to-head randomized clinical trial³



1. Roubille C, et al. *Ann Rheum Dis*. 2015;74:480-489. 2. Kang EH, et al. *J Am Heart Assoc*. 2018;7:e007393. 3. Giles JT, et al. *Arthritis Rheumatol*. 2020;72:31-40.

RA Treatments and Comorbid Disease Considerations from the ACR Treatment Guideline

RA treatments and comorbid disease considerations	
Recommendations	Certainty of evidence
Previous serious infection Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with a serious infection within previous 12 months who have moderate-to-high disease activity despite csDMARD monotherapy Addition of/switching to DMARDs is conditionally recommended over initiation/dose escalation of glucocorticoids for patients with a serious infection within previous 12 months who have moderate-to-high disease activity	Very low Very low
Pulmonary disease Methotrexate is conditionally recommended over alternative DMARDs for treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease who have moderate-to-high disease activity	Very low
Heart failure Addition of a non-TNFi DMARD or tsDMARD is conditionally recommended over addition of a TNFi for patients with New York Heart Association (NYHA) class III or IV heart failure and an inadequate response to csDMARDs Switching to a non-TNFi bDMARD or tsDMARD is conditionally recommended over continuation of a TNFi for patients taking a TNFi who develop heart failure	Very low Very low

Fraenkel L, et al. *Arthritis Care Res.* 2021;73:924-939.

RA Treatments and Comorbid Disease Considerations from the ACR Treatment Guideline (continued)

RA treatments and comorbid disease considerations	
Recommendations	Certainty of evidence
Hepatitis B infection Prophylactic antiviral therapy is strongly recommended over frequent monitoring alone for patients initiating rituximab who are hepatitis B core antibody positive (regardless of hepatitis B surface-antigen status) Prophylactic antiviral therapy is strongly recommended over frequent monitoring alone for patients initiating any bDMARD or tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen positive Frequent monitoring alone is conditionally recommended over prophylactic antiviral therapy for patients initiating a bDMARD other than rituximab or a tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen negative	Very low Very low Very low
Lymphoproliferative disorder Rituximab is conditionally recommended over other DMARDs for patients who have a previous lymphoproliferative disorder for which rituximab is an approved treatment and who have moderate-to-high disease activity	Very low

Fraenkel L, et al. *Arthritis Care Res.* 2021;73:924-939.

Conclusions

- RA is a chronic inflammatory disease with significant morbidity and disability if left untreated
- Advances in our understanding of RA pathogenesis have led to the development of new and more effective therapies; most recently, these have included newly developed agents that block JAK signaling
- Optimal approach to therapy needs to consider comorbidities, quality of life, T2T, tailoring regimens when needed, and promoting strategies that improve adherence

Case Study: Helen

Case Study: Helen

- Helen is 55 years old and has had RA for 10 years. She was initially treated with MTX, but a TNF inhibitor was added 4 years ago to control worsening disease activity.
- This combination worked very well for years, but she began to notice stiffness and pain in her joints in the days prior to her next injection. Her rheumatologist tried a different TNF inhibitor, but after 5 months, she is experiencing even more stiffness and swelling.
- She is using an over-the-counter NSAID to help with her symptoms, which have begun to interfere with her hobbies and even her activities of daily living.
- Helen is seropositive for both anti-CCP and RF. She smoked a half pack of cigarettes daily for many years but quit smoking after she was diagnosed with RA. She has treated hypertension, and her level of control has always been excellent.

NSAID = non-steroidal antiinflammatory drug.

Case Study: Question #1

What RA treatment options are available for Helen?

- A. Try a third TNF inhibitor
- B. Switch methotrexate to a different non-biologic DMARD
- C. Add low dose prednisone
- D. Start a non-TNF inhibitor biologic
- E. Start a JAK inhibitor

Case Study: Treatment Considerations

- There are actually quite a few treatment options for Helen.
- A third TNF inhibitor is not likely to be the best option, since she has been on a second TNF inhibitor for 5 months with no improvement.
- Changing MTX to a different non-biologic DMARD could help some, but she will still be treated with the same ineffective TNF inhibitor.
- With many treatment options available that have fewer side effects than corticosteroids, starting prednisone is not ideal. However, it could be used short term to improve symptoms while additional therapies are initiated.
- A number of non-TNF inhibitor biologics, including abatacept, IL-6 inhibitors, or rituximab, are appropriate options to consider for her.
- A JAK inhibitor is also an option for her. It should be discussed with her that higher rates of MIs were seen in older RA patients with CV risk factors taking a JAK inhibitor compared with etanercept. It should be noted that the absolute risk was quite low, and she does not fit the risk profile that was most at risk in the ORAL Surveillance trial.

Case Study: Another Treatment Consideration

- Helen and her rheumatologist decide to start a JAK inhibitor.
- She remembers a television commercial where shingles was mentioned as a possible side-effect of this type of agent.
- She reports that she had chickenpox as a child.

Case Study: Question #2

What do you tell her about the risk of shingles?

- A. Don't worry, the risk is rare
- B. If you didn't get shingles with the DMARDs you have been on, you won't get it now
- C. She should be vaccinated with live zoster vaccine
- D. She should be vaccinated with recombinant zoster vaccine

Case Study: Treatment Considerations About Shingles

- The risk of zoster is higher for IL-6 and JAK inhibitors than for MTX or etanercept.
- Now is a good opportunity to vaccinate her with recombinant zoster vaccine (Shingrix®) but not live zoster vaccine (Zostavax®).
- Ideally, the entire vaccination course (2 doses) would happen several weeks prior to starting the JAK inhibitor to ensure maximal response.
- The minimum time between doses is 8 weeks.
- You opt to continue her current therapy until she can get both doses of recombinant zoster vaccine and wait an additional 2 weeks until starting the JAK inhibitor.

Case Study: Pat

Case Study: Pat

- Pat is a 66-year-old woman who has had RA for 7 years. She was initially treated with MTX and did well on it for several years. When she began having more stiffness and swelling 2 years ago, a TNF inhibitor was added. It was moderately helpful, but she never achieved LDA or remission despite trying 2 different TNF inhibitors.
- She is currently taking MTX 25 mg per week and is using daily NSAIDs to help with symptoms. She stopped her TNF inhibitor 3 months ago because she did not think it was helping; her joint swelling and stiffness have gotten worse.
- She has 8 swollen and 10 tender joints; her CRP is elevated at 10 mg/dL.
- She has osteopenia based on her last DXA scan, with a FRAX score appropriate for a bisphosphonate, but she did not start it.
- Her BMI is 32 (kg/m²). Half of your time during appointments is spent discussing weight-loss strategies, but she never seems to lose any weight between visits.

DXA = dual-energy x-ray absorptiometry (scan); FRAX = Fracture Risk Assessment Tool; BMI = body mass index.

Case Study: Question #1

Which treatment option or options are best for Pat?

- A. Try another TNF inhibitor
- B. Add sulfasalazine and hydroxychloroquine to MTX
- C. Add abatacept
- D. Add rituximab
- E. Add an IL-6 blocker
- F. Add a JAK inhibitor
- G. Start 20 mg of prednisone and taper it over the next 3 months, then reevaluate

Case Study: Follow-Up

- When you review Pat's medical record, you see that she had a deep venous thrombosis 15 years ago.
- She was anticoagulated for 6 months and has not had a recurrence since then.

Case Study: Question #2

**Does this information change
your management plan for Pat?**

Case Study: VTE Risk

- Age, elevated BMI, and prior history of thromboembolic disease have been identified as risk factors for VTE in clinical trials of JAK inhibitors.
- Although overall risk of VTE is low among patients treated with JAK inhibitors (about 1 in every 200 or less), the risk may be higher in those with risk factors, especially those with prior VTE.
- The European Medicines Agency recommends not using JAK inhibitors in patients with VTE risk factors.

Thank You!

Q&A

**Disease Modification in Individuals with Moderate-to-Severe Rheumatoid Arthritis:
Optimizing Treatment Through the Finely Tuned Selectivity for JAKs**

Resource	Address
Burmester G, Cohen S, Winthrop K, et al. Long-term safety profile of upadacitinib in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Presented at: ACR Convergence; November 9, 2021; Abstract 1691.	https://acrabstracts.org/abstract/long-term-safety-profile-of-upadacitinib-in-patients-with-rheumatoid-arthritis-psoriatic-arthritis-or-ankylosing-spondylitis/
Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. <i>Lancet.</i> 2013;381:451-460.	https://pubmed.ncbi.nlm.nih.gov/23294500/
Desai RJ, Pawar A, Weinblatt ME, Kim SC. Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: An observational cohort study. <i>Arthritis Rheumatol.</i> 2019;71:892-900.	https://pubmed.ncbi.nlm.nih.gov/30552833/
Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): A phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet.</i> 2017;390:457-468.	https://pubmed.ncbi.nlm.nih.gov/28629665/
Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care Res (Hoboken).</i> 2021;73:924-939.	https://pubmed.ncbi.nlm.nih.gov/34101387/
Fragoulis GE, Brock J, Basu N, McInnes IB, Siebert. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. <i>J Allergy Clin Immunol.</i> 2021;148:941-952.	https://pubmed.ncbi.nlm.nih.gov/34450118/
Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial. <i>Lancet.</i> 2018;391:2513-2524.	https://pubmed.ncbi.nlm.nih.gov/29908670/
Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. <i>N Engl J Med.</i> 2016;374:1243-1252.	https://pubmed.ncbi.nlm.nih.gov/27028914/

Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. <i>J Clin Med.</i> 2019;8:938.	https://pubmed.ncbi.nlm.nih.gov/31261785/
Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. <i>N Engl J Med.</i> 2020;383:1511-1521.	https://pubmed.ncbi.nlm.nih.gov/33053283/
Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. <i>Ann Rheum Dis.</i> 2010;69:631-637.	https://pubmed.ncbi.nlm.nih.gov/20215140/
Ytterberg SR, Bhatt DL, Mikuls T, et al. Safety and efficacy of tofacitinib vs TNF inhibitors in RA patients aged 50 years or older with one or more cardiovascular risks: Results from a phase 3b/4 randomized safety trial. Presented at: ACR Convergence; November 7, 2021; Abstract 831.	https://acrabstracts.org/abstract/safety-and-efficacy-of-tofacitinib-vs-tnf-inhibitors-in-ra-patients-aged-50-years-or-older-with-one-or-more-cardiovascular-risks-results-from-a-phase-3b-4-randomized-safety-trial/